title: Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
abstract: OBJECTIVE
  Urokinase plasminogen activator receptor (uPAR) plays a central role during cancer invasion by facilitating pericellular proteolysis. We initiated the prospective 'Copenhagen uPAR Prostate Cancer' study to investigate the significance of uPAR levels in prostate cancer (PCa) patients.
  
  
  METHODS
  Plasma samples and clinical data from patients with newly diagnosed PCa have been collected prospectively. The uPAR forms have been measured in plasma using time-resolved fluorescence immunoassays.
  
  
  RESULTS
  The level of intact uPAR(I-III) did not differ. Plasma uPAR(I-III) + uPAR(II-III) levels and uPAR(I) levels were significantly higher in hormone-naive and castrate-resistant patients compared with patients with localized disease (both: p < 0.0001).
  
  
  CONCLUSIONS
  Our results show that cleaved uPAR forms are significantly increased in patients with advanced PCa.
authors.affiliation: Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Solvej
authors.initials: S
authors.lastname: Lippert
authors.affiliation: Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Kasper D
authors.initials: KD
authors.lastname: Berg
authors.affiliation: The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.|Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
authors.forename: Gunilla
authors.initials: G
authors.lastname: Høyer-Hansen
authors.affiliation: The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.|Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
authors.forename: Ida K
authors.initials: IK
authors.lastname: Lund
authors.affiliation: Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Peter
authors.initials: P
authors.lastname: Iversen
authors.affiliation: The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.|Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.
authors.forename: Ib J
authors.initials: IJ
authors.lastname: Christensen
authors.affiliation: Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Klaus
authors.initials: K
authors.lastname: Brasso
authors.affiliation: Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
authors.forename: Martin A
authors.initials: MA
authors.lastname: Røder
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D016208:Databases, Factual; D003718:Denmark / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood*; D059748:Proteolysis; D055293:Receptors, Urokinase Plasminogen Activator / Q000097:blood* / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; C524898:PLAUR protein, human; D055293:Receptors, Urokinase Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator
keywords: prostate cancer; uPA; uPAR; urokinase plasminogen activator receptor